REGENXBIO to Attend May 2024 Investor Conferences

REGENXBIO Inc., based in Rockville, Md., announced its participation in two significant upcoming investor conferences. The first is the BofA Securities Health Care Conference 2024, where a fireside chat is scheduled for Wednesday, May 15, 2024, at 2:20 p.m. ET in Las Vegas, NV. The second event is the Stifel 2024 Tailoring Genes Genetic Medicines Forum, with a fireside chat set for Tuesday, May 28, 2024, at 4:10 p.m. ET, conducted virtually.

Both presentations will be accessible via live webcast through the Investors section of REGENXBIO's website, with archived replays available for approximately 30 days post-presentation.

REGENXBIO Inc. is a prominent clinical-stage biotechnology firm dedicated to improving lives through gene therapy. Established in 2009, the company has been at the forefront of developing AAV Therapeutics, a novel class of gene therapy medicines. Their robust pipeline includes treatments for retinal and rare diseases, such as ABBV-RGX-314 for wet AMD and diabetic retinopathy, developed in partnership with AbbVie, RGX-202 for Duchenne muscular dystrophy, and RGX-121 for MPS II. Their AAV Therapeutic platform has been used to treat thousands of patients, including with Novartis' ZOLGENSMA for spinal muscular atrophy.

AAV Therapeutics are designed as one-time treatments, aiming to radically transform healthcare delivery for millions.